linjc16/ctgov huggingface dataset:
The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions

Study Overview
=================
Brief Summary
-----------------
ERCP with brush cytology has a poor to moderate accuracy in unclear biliary lesions. Endoscopic ultrasound (EUS) with fine needle aspiration (FNA) for cytology may override some of these shortcomings. The current prospective study, performed in a tertiary University center, aims to study the feasibility, the accuracy and the clinical value of combinatory ERCP and EUS in unclear biliary lesions.

Detailed Description
-----------------
The eligible study participants with unclear biliary lesions referred for an ERCP to the Sahlgrenska Univeristy Hospital endoscopy unit will be subjected to ERCP with/without brush cytology followed by EUS with/without FNA. The results of ERCP and EUS will be compared to the pathology report of surgical specimens in resected patients or to clinical follow up at 12 months post-EUS in non-resected patients.

Official Title
-----------------
Sahlgrenska EUS ERCP Study

Conditions
-----------------
Neoplasms, Biliary Stricture, Biliary Tract Neoplasms, Biliary Tract Diseases

Intervention / Treatment
-----------------
* Procedure: Combinatory EUS and ERCP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with unclear lesions or strictures in the biliary tract referred for endoscopy work up Exclusion Criteria: Patients unwilling to participate Patients unfit for EUS and ERCP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy | Overall accuracy of ERCP and EUS | 12 months post-EUS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse event rate | The number of patients ending up with some type of complication related to ERCP or EUS | 30 days post-EUS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endosonography, Endoscopic retrograde choledochography
Frailty Prevalence in Surgical European Patients. European Prospective Cohort Stufy of the Prevalence of Frailty in Surgical Patients.

Study Overview
=================
Brief Summary
-----------------
European prospective one day cohort study. Analysis of the prevalence of frailty and predefined 30-day postoperative complications in adult patients undergoing emergency or elective surgery.

Official Title
-----------------
Frailty Prevalence in Surgical European Patients. European Prospective Cohort Stufy of the Prevalence of Frailty in Surgical Patients.

Conditions
-----------------
Frailty

Intervention / Treatment
-----------------
* Other: There is no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over the age of 18 who will undergo emergency or elective surgery with an intended hospital stay of more than 24 hours and any type of anesthesia. Exclusion Criteria: Outpatient (ie. day case) surgery, obstetric analgesia or anesthesia, organ transplant surgery, cardiac surgery, neurosurgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: There is no intervention|There is no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of patients with frailty identified in the preoperative assessment in both elective and emergency surgery, as well as frailty's severity. |  | 30 days |
Genetic Predictors of Incident Cardiovascular Disease

Study Overview
=================
Brief Summary
-----------------
To evaluate how current genetic information about cardiovascular disease susceptibility genes contributes to the prediction of future cardiovascular disease outcomes.

Detailed Description
-----------------
BACKGROUND: During the 1980s and 1990s, genetic research in cardiovascular disease (CVD), as well as other common chronic diseases, has been dominated by single gene linkage and association studies focused on understanding of the genetics of prevalent disease. Rarely have there been studies of the longitudinal predictive value of these genetic variations. Furthermore, few studies have attempted to address the complex and high-dimensional genetic reality that underlies an individual's risk of disease. A crucial next step in CVD genetic research is the evaluation of the contribution of variations in many genes simultaneously, and their interactions with traditional risk factors, to the longitudinal prediction of CVD in individuals and families. DESIGN NARRATIVE: The study uses participants from the Rochester Family Heart Study (RFHS) which provides one of the richest genetic epidemiological resources for this type of study. The RFHS represents 3941 individuals distributed among 552 three- generation pedigrees ascertained without regard to health status during two phases of collection. Phase I was from 1984 - 1988 and Phase II was from 1988 - 1991. These participants have extensive demographic, physiological, genetic, and clinical information measured at baseline. This study builds upon this already established resource by conducting a longitudinal follow-up of the RFHS participants to address two central questions: 1) Do measured genetic variations in known susceptibility genes provide additional predictive information about risk of future CVD outcomes beyond the information provided by more traditional risk factors? and 2) Do these measured genetic variations explain patterns of disease aggregation in families and can these patterns be used to predict disease in future generations?

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

Study Overview
=================
Brief Summary
-----------------
H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.

Official Title
-----------------
Clinical Research of the Molecular Phenotype Distribution of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy

Conditions
-----------------
Spinal Tumor

Intervention / Treatment
-----------------
* Other: Genetic testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation. Exclusion Criteria: The tumor is recurrent or has been treated before operation.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| children<br>age<=17 | Other: Genetic testing<br>* To determine whether H3F3AK27M exist in spinal glioma<br>|
| adult<br>age>17 | Other: Genetic testing<br>* To determine whether H3F3AK27M exist in spinal glioma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive | positive of H3F3AK27M | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
H3F3AK27M
Trial Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial

Study Overview
=================
Brief Summary
-----------------
Hypothesis: Home-based cardiac rehabilitation is as effective as comprehensive centre-based cardiac rehabilitation in patients older than 65 years.

Detailed Description
-----------------
Participation in cardiac rehabilitation is known to reduce mortality and morbidity and increase health related quality of life. However, participation rate are low among elderly cardiac patients with coronary heart disease. Home-based cardiac rehabilitation could be an attractive alternative to the centre-based programmes but studies investigating the effect of these programmes are limited and even less is known about the effect among the elderly.

Official Title
-----------------
RCT Comparing Home-based Cardiac Rehabilitation With Comprehensive Centre-based Cardiac Rehabilitation and Usual Care in Patients Older Than 65 Years With Coronary Heart Disease. The HOMEBASE Trial.

Conditions
-----------------
Coronary Heart Disease

Intervention / Treatment
-----------------
* Other: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Event of coronary heart disease (new myocardial infarction, CABG or PCI) Exclusion Criteria: Care home patients. Serious disability incompatible with rehabilitation. Social circumstances incompatible with participation.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Exercise intervention<br>Exercise intervention and lifestyle counseling at centre or exercise intervention at home | Other: Exercise<br>* Exercise intervention and lifestyle counseling at centre or exercise intervention at home<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise capacity |  | At baseline and after 3,6 and 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure, cholesterol, body composition, HRQL |  | At baseline and after 3, 6 and 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac Rehabilitation, Exercise, Heart failure, Coronary heart disease
Evaluation of Frail Elderly in Ambulatory Primary Care

Study Overview
=================
Brief Summary
-----------------
Evaluate the sensitivity of the GERONTOPOLE scale, used by general practitioners in primary care outpatients for the diagnosis of frailty in non-dependent people more than 65 years old, using as reference the évaluation gériatrique standardisée clinique (EGS)

Official Title
-----------------
Evaluation of Frail Elderly in Ambulatory Primary Care

Conditions
-----------------
Frailty

Intervention / Treatment
-----------------
* Diagnostic Test: Assessement with GERONTOPOLE scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Independent patients Exclusion Criteria: Dependent outpatient, assessed with a activity of daily living (ADL) score < 6/6 outpatient with occuring severe health episode less than a month before inclusion

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Assessement with GERONTOPOLE scale|The practitionner assesses the frailty of the elderly outpatient with the GERONTOPOLE scale and compares it with the évaluation gériatrique standardisée (GDS)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess the sensitivity of the GERONTOPOLE scale | by practitionner | 2 years |
Medical Assistance for the Procreation and Risk of Thrombosis.

Study Overview
=================
Brief Summary
-----------------
This study aims at evaluating clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation. Secondary outcomes are : 1) to describe the incidence and risk factors of arterial and venous thrombosis in women undergoing assisted reproductive technology and 2)to identify the incidence and risk factors for ovarian hyperstimulation syndrome in these women

Detailed Description
-----------------
All women undergoing an assisted reproductive tecnology in order to receive an in vitro fertilization in French centers will be included in the study. These women will be followed up until 12 months after ovarian stimulation if they get pregnant or until 3 months if the stimulation does not lead to pregnancy. Risk factors for thrombosis and ovarian hyperstimulation syndrome will be collected in each woman. At each visit, women will be asked whether arterial and/or venous thrombosis had occured.

Official Title
-----------------
Assistance Médicale à la Procréation et Risque Thrombotique

Conditions
-----------------
Ovarian Hyperstimulation Syndrome, Cardiovascular Diseases, Embolism and Thrombosis

Intervention / Treatment
-----------------
* Other: ovarian stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women undergoing ovarian stimulation in order to receive in vitro fertilization Exclusion Criteria: Age<18 years Women refusing to particpate in the study No health coverage Women under guardianship Women receiving therapeutic doses of anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women undergoing ART<br>Observation of the incidence of venous and arterial thrombosis following ovarian stimulation | Other: ovarian stimulation<br>* evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of professional clinical practice for ovarian stimulation care |  | Until 12 months followin ovarian stimulation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Arterial and/or venous thrombosis |  | until 12 months following ovarian stimulation | 
| Risk factors for thrombosis |  | until 12 months following ovarian stimulation |
Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this prospective randomized controlled trial was to compare intensive insulin therapy with a carbohydrate restrictive strategy in patients with acute ischemic stroke evaluating the outcome through the Glasgow Outcome Scale Extended, hospital mortality and NIHSS during the ICU stay.

Official Title
-----------------
Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

Conditions
-----------------
Acute Ischemic Stroke

Intervention / Treatment
-----------------
* Other: Carbohydrate restrictive strategy
* Drug: Intensive insulin therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with acute ischemic stroke defined as: Abrupt onset of focal neurologic deficit No evidence of intracranial hemorrhage at non-contrasted CT scan. Exclusion Criteria: Age below 18 Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Carbohydrate restrictive strategy | Other: Carbohydrate restrictive strategy<br>* Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.<br>|
| Active Comparator: 2<br>Intensive insulin therapy | Drug: Intensive insulin therapy<br>* Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurological outcome through the Glasgow Outcome Scale Extended |  | At least 4 months after hospital discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NIHSS during ICU stay |  | ICU stay | 
| Hospital mortality |  | Hospital stay |
The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children

Study Overview
=================
Brief Summary
-----------------
Stridor is a respiratory noise caused by partial obstruction of the large airways at the level of the pharynx, larynx and/or trachea. The second most common cause of stridor is vocal cord paralysis. Awake nasolaryngoscopyn (ANL) is regarded as the gold standard for the diagnosis of laryngomalacia. However, ANL has some drawbacks as it may cause discomfort for the patient and the laryngeal view may be obscured due to patient movement or anatomical variations. Ultrasound (US) is a noninvasive, painless, radiation free, well tolerated imaging technique. Evaluation of the dynamic characteristics of the glottis by US revealed perfect reliability in comparison to nasolryngoscopy suggesting that US can be useful in the assessment of laryngeal adduction. The investigator hypothesize that laryngeal US can be an accurate and reliable adjunct in the diagnosis of functional and anatomical causes of stridor and dysphonia in the pediatric population.

Official Title
-----------------
The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children

Conditions
-----------------
Stridor, Vocal Cord Paralysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre will undergo US of the larynx. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: laryngeal ultrasound stridor<br>Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre. | |
| Other: laryngeal ultrasound -control<br>Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of participants that will be diagnosed with anatomical and functional causes of stridor and dysphonia by US in comparisom with ANL | i.e. vocal cord nodules, vocal cord paralysis, vocal cord cyst etc. | 2014-2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stridor, Vocal Cord Paralysis (VCP), Ultrasound (US)
Allergenic Effect of Ambrosia in Israel

Study Overview
=================
Brief Summary
-----------------
Background: Respiratory allergic reaction causes great suffering to millions of people worldwide. One of the most known allergen- is the pollen from vegetation, ragweed. Genus Ambrosia Ambrosia belonged to the complex ragweed flowers are pollinated by the wind and the plant's male flowers produce large quantities of small grains of pollen and airborne over long distances and those causes allergic reactions. The plant blooms between June and October, creating a second wave after wave of allergy caused by spring blossoms. This plant originated in North America has invaded many areas in Europe and in recent years, taking over large areas in Israel, Hula Valley and northern Acre Emek Hefer for a pen and layers to the south. After ragweed plants are based in particular they spread quickly and invade agricultural fields and significantly reduce the crop. High allergenic ragweed is a health hazard to humans. Ragweed plant investigated many aspects of North America and Europe in recent decades and extensive literature on ambrosia, but this is the first time ragweed study focuses on Israel. Working hypothesis and aims: Goal of this study is to identify the existence and nature of the sensitivity distribution of ragweed in Israel. Importance of research: A. Ragweed allergen testing and comparing the effect of exposure to plants on the sensitivity of the allergic Israeli patients B. The inclusion of ragweed allergen in the diagnostic and therapeutic panel

Conditions
-----------------
Allergy, Ambrosia, Ragweed

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: respiratory allergic patients Exclusion Criteria: non respiratory allergic patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |